Recent investigations have centered on the convergence of GLP|GIP|glucagon receptor agonist therapies and dopaminergic signaling. While GIP stimulators are increasingly employed for treating type 2 T2DM, their emerging consequences on reward circuits, specifically governed by dopaminergic network